Our Actions Related to COVID-19 and the Impact on Supply

Update: March 16, 2021

As the COVID-19 vaccine programs continue to roll-out in each country across the globe, we continue to watch the development of the pandemic and put in place the necessary safeguards to protect our employees, customers, suppliers and partners. At same time, we have implemented different steps to ensure sufficient supplies of meters and test strips are available for people with diabetes in all the markets in which our products are available.


Update: December 11, 2020

With the rising number of COVID-19 cases around much of the globe, we continue to adhere to local guidance and regulations to ensure the health and safety of our employees, customers and partners. Most employees are being advised to work from home and meetings are being held remotely, where possible.

In addition, we continue to monitor and optimize our supply chain to mitigate the ongoing challenges and to date have not experienced any notable supply disruptions or stock outages as a result of the pandemic.


Update: September 10, 2020

During the ongoing COVID-19 situation our teams remain focused on maintaining an uninterrupted supply of test strips and meters for people with diabetes, and we can confirm that we have not experienced any supply issues to date.

We continue to have measures in place to maintain health and safety of our employees, customers and partners.

Based on the current position, updates will only be provided on a quarterly basis going forward, unless the situation changes.


Update: May 19, 2020

We have continued to monitor the COVID-19 situation closely and can confirm that we are not seeing any issues with the supply of our test strips and meters due to COVID-19.

The measures that we are taking to maintain health and safety remain unchanged from our original statement on March 19, 2020 and there is no change from our update on April 17.


Update: April 17, 2020

The impact of COVID-19 on our ability to supply test strips and meters, and the measures that we are taking to maintain health and safety remain unchanged from our previous statement on March 19, 2020.

We continue to monitor the situation closely and will provide further updates as required.


March 19, 2020

At PHC Group and Ascensia Diabetes Care, the health and safety of our customers, employees and the patients we serve is our number one priority.

We are continuing to monitor the global impact of the COVID-19 outbreak and are taking all appropriate measures to keep our employees safe and minimize the effect on people who rely on our products and services.

At present, there appears to be no immediate impact on the supply of our test strips and meters, and we do not anticipate any short-term issues related to the supply of these products due to COVID-19.

Nonetheless, we are beginning to experience some transportation challenges, with enhanced screening putting pressure on road shipments at borders and the decline in the number of commercial flights affecting air freight availability. Although these are not directly impacting our ability to supply products, they may have an impact on supply in certain markets depending on how long we experience these limitations.

However, we have solid business continuity plans in place to manage our global supply and are working closely with our partners to ensure we are able to maintain production and supply of our strips and meters to all countries.

Our products are manufactured in Japan and Indonesia, where production is currently running without delays. Our product packaging and distribution facilities, which are managed by a third party vendor, are based in Poland and the US and are operating as normal. We will continue to monitor the COVID-19 situation and any impact it has on our supply chain on a regular basis.

This is a very dynamic situation with new information and guidance being issued from authorities on a regular basis, which we are adopting as appropriate for each market we operate in. We will assess the situation on an ongoing basis to determine what further actions we need to take and will issue any revised information via this website page. Please continue to visit this site for ongoing communications from our team related to this issue.